Skip to main content
Dryad logo

Pain in patients with Type 2 diabetes-related polyneuropathy is associated with vascular events and mortality

Citation

Lapin, Brittany et al. (2020), Pain in patients with Type 2 diabetes-related polyneuropathy is associated with vascular events and mortality, Dryad, Dataset, https://doi.org/10.5061/dryad.k3j9kd548

Abstract

Type 2 diabetes–related polyneuropathy (DPN) is associated with increased vascular events and mortality, but determinants and outcomes of pain in DPN are poorly understood. We sought to examine the effect of neuropathic pain on vascular events and mortality in patients without DPN, DPN with pain (DPN + P), and DPN without pain (DPN-P). A retrospective cohort study was conducted within a large health system of adult patients with type 2 diabetes from January 1, 2009 through December 31, 2016. Using an electronic algorithm, patients were classified as no DPN, DPN + P, or DPN-P. Primary outcomes included number of vascular events and time to mortality. Independent associations with DPN + P were evaluated using multivariable negative binomial and Cox proportional hazards regression models, adjusting for demographics, socioeconomic characteristics, and comorbidities. Of 43 945 patients with type 2 diabetes (age 64.6 ± 14.0 years; 52.1% female), 13 910 (31.7%) had DPN: 9104 DPN + P (65.4%) vs 4806 DPN-P (34.6%). Vascular events occurred in 4538 (15.1%) of no DPN patients, 2401 (26.4%) DPN + P, and 1006 (20.9%) DPN-P. After adjustment, DPN + P remained a significant predictor of number of vascular events (incidence rate ratio [IRR] = 1.55, 95% CI, 1.29-1.85), whereas no DPN was protective (IRR = 0.70, 95% CI, 0.60-0.82), as compared to DPN-P. Compared to DPN-P, DPN + P was also a significant predictor of mortality (hazard ratio = 1.42, 95% CI, 1.25-1.61). Our study found a significant association between pain in DPN and an increased risk of vascular events and mortality. This observation warrants longitudinal study of the risk factors and natural history of pain in DPN.

 

Methods

A retrospective cohort study was conducted including adult patients (age ≥ 18 years) with a diagnosis of type 2 diabetes within the study period of January 1, 2009 through December 31, 2016, living in the Cuyahoga and the surrounding 7-county region, and seen within the Cleveland Clinic system at least once within the 8-year study period. Patients with type 1 diabetes were excluded. Data were extracted from the enterprisewide electronic health record (EHR) at Cleveland Clinic (Epic Verona, Wisconsin).

Funding

Novartis Pharmaceuticals Corporation